Surface-fill hydrogel attenuates the oncogenic signature of complex anatomical surface cancer in a single application

Tumours that grow on organ surfaces are difficult to eradicate as the complex topology of underlying tissues might hamper accessibility to tumour foci even after surgery. In this paper the authors engineer a peptide-based hydrogel that can be applied on surface tumours before or after resection, conform to the tissue underneath and release therapeutics. Tumours growing in a sheet-like manner on the surface of organs and tissues with complex topologies represent a difficult-to-treat clinical scenario. Their complete surgical resection is difficult due to the complicated anatomy of the diseased tissue. Residual cancer often responds poorly to systemic therapy and locoregional treatment is hindered by the limited accessibility to microscopic tumour foci. Here we engineered a peptide-based surface-fill hydrogel (SFH) that can be syringe- or spray-delivered to surface cancers during surgery or used as a primary therapy. Once applied, SFH can shape change in response to alterations in tissue morphology that may occur during surgery. Implanted SFH releases nanoparticles composed of microRNA and intrinsically disordered peptides that enter cancer cells attenuating their oncogenic signature. With a single application, SFH shows efficacy in four preclinical models of mesothelioma, demonstrating the therapeutic impact of the local application of tumour-specific microRNA, which might change the treatment paradigm for mesothelioma and possibly other surface cancers.

Automated summary

The authors engineered a peptide-based surface-fill hydrogel (SFH) that can be applied to surface cancers during surgery to effectively reduce the risk of tumor recurrence post-surgery.